Get the latest insights into Centrexion Therapeutics.

Recent News

Centrexion Therapeutics to Present Clinical Data from Pipeline of Chronic Pain Treatments at the 11th Annual Pain and Migraine Therapeutics Summit

Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017

Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting

Centrexion Therapeutics Provides Updates and Advancements for Pipeline of Chronic Pain Treatments

Centrexion Therapeutics Names Shawn Tomasello to its Board of Directors

Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain

Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology (EULAR 2017)

Centrexion Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatology’s 2017 Annual Congress

Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting

Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA

Centrexion Therapeutics to Present Late-Breaking Poster at the 33rd Annual American Academy of Pain Medicine Meeting

Centrexion Therapeutics to Present at the 19th Annual BIO CEO & Investor Conference

Centrexion Therapeutics Announces Highly Statistically Significant Topline Results from Phase 2b Study of CNTX-4975 in Patients with Knee Osteoarthritis Pain

Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Morton’s Neuroma

Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim